Mironid® Limited

Mironid® Limited is a biotechnology company based in Scotland, UK, dedicated to discovering and developing innovative small-molecule therapeutics. Founded in 2014, the company focuses on modulating key PDE4 enzymes and other cAMP-degrading phosphodiesterase enzymes to address unmet medical needs in conditions such as Autosomal Dominant Polycystic Kidney Disease (ADPKD), degenerative kidney diseases, chronic inflammatory diseases, and cancer.

The company is currently advancing its lead development candidate for ADPKD through pre-clinical studies, with plans to enter clinical trials. Mironid also has broader programs targeting degenerative kidney diseases, chronic inflammatory diseases, and cancer, utilizing cell signaling modulation to create differentiated therapies. With a team of approximately 15-17 employees, Mironid has raised £35 million to support its research and development efforts, aiming to transform treatment options for life-threatening hereditary kidney diseases.